MedTrace Logo

Compassionate Use of Tetrabenazine in the Treatment of Abnormal Movements

NCT00642057 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2023-03-24

No results posted yet for this study

Summary

Although the results of studies looking at tetrabenazine have shown its effectiveness in the management of hyperkinetic(too much) movement disorders, it has not been made available in the U.S. The drug must be obtained from Cambridge Laboratories, the distributor, using an individual IND (#16,161). The cost of the drug is passed on to the patient. The purpose of the protocol is to provide an efficacious drug, with few side effects, in an attempt to get rid of a variety of incapacitating dyskinesias (abnormal movements).

Conditions

  • Hyperkinetic Movement Disorders

Interventions

DRUG

tetrabenazine

25 mg titrated to optimal dose per patient

Sponsors & Collaborators

  • Joseph Jankovic

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00642057 on ClinicalTrials.gov